COLL
Collegium Pharmaceutical, Inc. NASDAQ Listed May 7, 2015$33.54
-0.42%
vs $33.68
Mkt Cap $1.3B
52w Low $29.57
19.6% of range
52w High $49.84
50d MA $34.14
200d MA $39.30
P/E (TTM)
19.4x
EV/EBITDA
4.6x
P/B
3.5x
Debt/Equity
3.1x
ROE
5.6%
P/FCF
4.1x
RSI (14)
49.70
ATR (14)
$1.32
Beta
0.77
50d MA
$34.14
200d MA
$39.30
Avg Volume
417.2K
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
100 Technology Center Drive · Stoughton, MA 02072 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 36.51 | +2.7% | +7.7% | -3.9% | -5.3% | -0.3% | -2.3% | — |
| Feb 26, 2026 | AMC | 2.14 | 2.04 | -4.7% | 44.22 | -1.6% | -5.8% | -0.2% | -3.9% | -1.0% | -5.9% | — |
| Nov 6, 2025 | AMC | 1.86 | 2.25 | +21.0% | 40.66 | +0.6% | +4.0% | +2.9% | +3.0% | +5.6% | -2.0% | — |
| Aug 7, 2025 | AMC | 1.62 | 1.68 | +3.7% | 32.94 | +1.1% | +6.0% | +3.5% | +4.8% | -0.0% | -1.8% | — |
| May 8, 2025 | AMC | 1.43 | 1.49 | +4.2% | 27.27 | +8.8% | +5.9% | +2.3% | +0.8% | -2.4% | +0.9% | — |
| Feb 27, 2025 | AMC | 1.54 | 1.77 | +14.9% | 28.42 | +6.7% | +2.2% | -2.1% | -1.4% | +1.5% | +4.7% | — |
| Nov 7, 2024 | AMC | 1.59 | 1.61 | +1.3% | 34.71 | -4.9% | -7.3% | +0.1% | -2.4% | -3.9% | +0.3% | — |
| Aug 8, 2024 | AMC | 1.49 | 1.62 | +8.7% | 35.32 | -2.0% | +0.5% | +0.3% | +3.1% | -6.6% | +3.4% | — |
| May 9, 2024 | AMC | 1.47 | 1.45 | -1.4% | 37.86 | -12.8% | -16.8% | +2.1% | +3.5% | +2.1% | -0.9% | — |
| Feb 22, 2024 | AMC | 1.38 | 1.58 | +14.5% | 32.81 | +5.2% | +10.8% | +0.6% | +0.6% | -0.6% | +0.4% | — |
| Nov 7, 2023 | AMC | 1.22 | 1.34 | +9.8% | 21.68 | +9.8% | +6.6% | +5.6% | +0.3% | +2.9% | -0.3% | — |
| Aug 3, 2023 | AMC | 1.22 | 1.26 | +3.3% | 22.02 | +6.5% | +6.7% | +2.4% | +0.2% | -0.6% | +0.8% | — |
| May 4, 2023 | AMC | 1.33 | 1.32 | -0.8% | 22.20 | +1.3% | +3.2% | +2.2% | +0.5% | -1.9% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.30 | $36.31 | +0.0% | -2.4% | -2.0% | -4.3% | +0.1% | +0.5% |
| Mar 19 | Needham | Maintains | Buy → Buy | — | $34.80 | $35.64 | +2.4% | +4.3% | -2.4% | -2.0% | -4.3% | +0.1% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $45.75 | $41.75 | -8.7% | -3.3% | -5.8% | -0.2% | -3.9% | -1.0% |
| Jan 9 | Barclays | Maintains | Overweight → Overweight | — | $48.78 | $48.77 | -0.0% | -6.6% | +5.7% | -1.8% | -1.5% | +0.7% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.78 | $48.77 | -0.0% | -6.6% | +5.7% | -1.8% | -1.5% | +0.7% |
| Jan 8 | Needham | Maintains | Buy → Buy | — | $47.26 | $47.73 | +1.0% | +3.2% | -6.6% | +5.7% | -1.8% | -1.5% |
| Nov 7 | Truist | Maintains | Buy → Buy | — | $40.66 | $40.91 | +0.6% | +4.0% | +2.9% | +3.0% | +5.6% | -2.0% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.66 | $40.91 | +0.6% | +4.0% | +2.9% | +3.0% | +5.6% | -2.0% |
| Oct 28 | Needham | Maintains | Buy → Buy | — | $34.82 | $34.63 | -0.5% | +1.7% | -1.7% | +2.4% | +1.0% | +0.3% |
| May 9 | Piper Sandler | Maintains | Neutral → Neutral | — | $27.27 | $29.66 | +8.8% | +5.9% | +2.3% | +0.8% | -2.4% | +0.9% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $25.41 | $24.79 | -2.4% | +3.8% | -6.4% | +6.6% | +1.6% | +1.5% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.05 | $30.43 | +1.3% | +1.7% | -1.3% | -0.6% | -1.3% | +0.5% |
| Feb 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $31.20 | $30.81 | -1.2% | -0.9% | -0.7% | +0.8% | -0.4% | -1.0% |
| Jan 10 | Needham | Upgrade | Hold → Buy | — | $33.34 | $33.92 | +1.7% | -1.3% | +2.7% | -1.8% | -0.7% | +1.5% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.34 | $33.92 | +1.7% | -1.3% | +2.7% | -1.8% | -0.7% | +1.5% |
| Oct 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $36.64 | $36.80 | +0.4% | +2.9% | +0.7% | +1.4% | +2.1% | -1.0% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.24 | $38.52 | +0.7% | -1.6% | -1.1% | -1.3% | -1.7% | +0.4% |
| Aug 9 | Piper Sandler | Maintains | Neutral → Neutral | — | $35.32 | $34.61 | -2.0% | +0.5% | +0.3% | +3.1% | -6.6% | +3.4% |
| Aug 9 | Truist | Maintains | Buy → Buy | — | $35.32 | $34.61 | -2.0% | +0.5% | +0.3% | +3.1% | -6.6% | +3.4% |
| Jul 30 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $34.89 | $36.51 | +4.6% | +10.6% | -0.1% | +0.1% | -5.8% | -5.1% |
| Jun 7 | Jefferies | Upgrade | Hold → Buy | — | $31.36 | $32.57 | +3.9% | +5.8% | +0.4% | -2.2% | -2.1% | +0.2% |
| May 10 | Piper Sandler | Downgrade | Overweight → Neutral | — | $37.86 | $33.01 | -12.8% | -16.8% | +2.1% | +3.5% | +2.1% | -0.9% |
| May 10 | Needham | Downgrade | Buy → Hold | — | $37.86 | $33.01 | -12.8% | -16.8% | +2.1% | +3.5% | +2.1% | -0.9% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $37.99 | $37.97 | -0.1% | -4.2% | -1.9% | -1.6% | +0.7% | +0.1% |
| Feb 26 | Truist | Maintains | Buy → Buy | — | $36.35 | $36.36 | +0.0% | +0.6% | +0.6% | -0.6% | +0.4% | +1.1% |
| Feb 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.81 | $34.50 | +5.2% | +10.8% | +0.6% | +0.6% | -0.6% | +0.4% |
| Feb 2 | Needham | Maintains | Buy → Buy | — | $33.47 | $33.44 | -0.1% | -1.9% | +0.8% | +0.5% | -0.1% | +0.4% |
| Jan 4 | Truist | Maintains | Buy → Buy | — | $33.86 | $33.21 | -1.9% | -4.5% | -0.1% | -1.7% | +1.7% | +1.1% |
| Jan 4 | Jefferies | Downgrade | Buy → Hold | — | $33.86 | $33.21 | -1.9% | -4.5% | -0.1% | -1.7% | +1.7% | +1.1% |
| Jan 4 | Needham | Maintains | Buy → Buy | — | $33.86 | $33.21 | -1.9% | -4.5% | -0.1% | -1.7% | +1.7% | +1.1% |
| Aug 25 | Needham | Maintains | Buy → Buy | — | $23.51 | $23.84 | +1.4% | +1.5% | -1.6% | +1.4% | -1.0% | -0.7% |
| Aug 4 | Needham | Maintains | Buy → Buy | — | $22.02 | $23.46 | +6.5% | +6.7% | +2.4% | +0.2% | -0.6% | +0.8% |
| May 30 | Needham | Maintains | Buy → Buy | — | $22.53 | $22.58 | +0.2% | -3.2% | +1.2% | +1.3% | -3.2% | -2.6% |
| May 5 | Needham | Maintains | Buy → Buy | — | $22.20 | $22.49 | +1.3% | +3.2% | +2.2% | +0.5% | -1.9% | +0.2% |
| Apr 19 | Needham | Maintains | Buy → Buy | — | $23.14 | $23.13 | -0.0% | -1.1% | -0.2% | +1.0% | +1.4% | -2.6% |
| Feb 24 | Needham | Maintains | Buy → Buy | — | $26.60 | $27.60 | +3.8% | +0.9% | -0.2% | -1.0% | +1.0% | +1.6% |
| Feb 8 | Needham | Maintains | Buy → Buy | — | $28.12 | $27.44 | -2.4% | -4.6% | -0.4% | +0.1% | +0.7% | -0.4% |
| Jan 5 | Needham | Maintains | Buy → Buy | — | $26.98 | $27.10 | +0.4% | +3.9% | +2.2% | -2.6% | +1.9% | -3.8% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $18.03 | $19.19 | +6.4% | +4.5% | +6.1% | -1.3% | -2.5% | +0.2% |
| Aug 8 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $20.10 | $19.41 | -3.4% | -3.0% | -0.8% | +2.3% | -3.0% | -2.1% |
| Apr 6 | Needham | Maintains | Buy → Buy | — | $20.08 | $20.00 | -0.4% | +4.0% | -1.1% | -0.6% | -4.1% | -2.1% |
| Feb 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.75 | $22.75 | +4.6% | +1.9% | +1.5% | -4.9% | -9.5% | +0.6% |
| Feb 15 | Needham | Maintains | Buy → Buy | — | $19.90 | $20.71 | +4.1% | +9.6% | +2.1% | -1.3% | -1.1% | +1.9% |
| Feb 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.90 | $20.71 | +4.1% | +9.6% | +2.1% | -1.3% | -1.1% | +1.9% |
| Nov 15 | Needham | Maintains | Buy → Buy | — | $19.48 | $20.50 | +5.2% | +2.7% | -0.7% | -1.5% | -2.6% | -1.0% |
| Nov 5 | Needham | Maintains | Buy → Buy | — | $19.35 | $18.99 | -1.9% | -1.5% | +6.7% | -0.0% | -0.6% | -0.4% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.84 | $20.81 | -16.2% | -17.3% | -3.1% | -4.4% | -2.0% | -2.3% |
| Aug 6 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $24.84 | $20.81 | -16.2% | -17.3% | -3.1% | -4.4% | -2.0% | -2.3% |
| Aug 6 | Needham | Maintains | Buy → Buy | — | $24.84 | $20.81 | -16.2% | -17.3% | -3.1% | -4.4% | -2.0% | -2.3% |
| Jan 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.69 | $22.45 | +3.5% | -2.4% | +1.8% | +1.2% | +2.1% | +7.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | Freund John Gordon | — | Sell | 20 | $34.05 | $681 | 83,952 | +0.58% | -0.92% |
| May 15, 2026 | Freund John Gordon | — | Sell | 4,127 | $34.54 | $143K | 83,972 | -0.09% | -0.85% |
| May 13, 2026 | Lurker Nancy | — | Sell | 4,500 | $35.97 | $162K | 18,017 | -0.38% | -1.02% |
| May 11, 2026 | BOHLIN GAREN G | — | Sell | 8,700 | $37.18 | $323K | 62,259 | -0.11% | +1.78% |
8-K · 5.02
!!! Very High
Collegium Pharmaceutical, Inc. -- 8-K 5.02: Executive Change
May 12
8-K · 2.02
!! High
Collegium Pharmaceutical, Inc. -- 8-K 2.02: Earnings Results
Collegium Pharmaceutical reported earnings results in an 8-K filing, with the full press release available as an exhibit for investor review of the company's operational and financial performance.
May 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of Dr. Fallon from the board removes a director whose contributions were significant, potentially signaling governance changes or internal disagreements that investors should monitor for strategic direction shifts.
Apr 7
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Collplant signed a $24M agreement with Corium, likely for technology licensing or partnership, potentially unlocking new revenue streams and validating its regenerative medicine platform's commercial value.
Mar 19
8-K · 7.01
! Medium
Collegium Pharmaceutical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Collegium Pharmaceutical furnished an investor presentation under Regulation FD Disclosure, suggesting the company is providing material non-public information to investors that must now be disclosed publicly.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 1,369,226 | $63M | Reduced | Dec 2025 |
| 2 | Principal Financial Group Inc | 1,313,662 | $61M | — | Dec 2025 |
| 3 | Janus Henderson Group Plc | 1,825,651 | $60M | New | Mar 2026 |
| 4 | Invesco Ltd. | 1,591,909 | $53M | Added | Mar 2026 |
| 5 | Renaissance Technologies Llc | 1,469,449 | $49M | Reduced | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 1,333,992 | $44M | New | Mar 2026 |
| 7 | Marshall Wace, Llp | 748,812 | $25M | Added | Mar 2026 |
| 8 | Arrowstreet Capital, Limited Partnership | 703,528 | $23M | Added | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 680,381 | $23M | New | Mar 2026 |
| 10 | Victory Capital Management Inc | 625,304 | $21M | Added | Mar 2026 |
| 11 | Qube Research & Technologies Ltd | 621,935 | $21M | Added | Mar 2026 |
| 12 | Two Sigma Investments, Lp | 590,116 | $20M | Added | Mar 2026 |
| 13 | D.e. Shaw & Co | 530,698 | $18M | Reduced | Mar 2026 |
| 14 | Northern Trust Corp | 361,889 | $12M | Added | Mar 2026 |
| 15 | Millennium Management | 360,826 | $12M | Added | Mar 2026 |
| 16 | Assenagon Asset Management S.a. | 312,598 | $10M | Reduced | Mar 2026 |
| 17 | Bank Of America Corp /de/ | 297,847 | $10M | Added | Mar 2026 |
| 18 | Jane Street Group, Llc | 190,763 | $9M | Reduced | Dec 2025 |
| 19 | Bank Of New York Mellon Corp | 225,705 | $7M | Reduced | Mar 2026 |
| 20 | Franklin Resources Inc | 174,362 | $6M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.33B
Enterprise Value
$1.83B
P/E (TTM)
19.39x
Forward P/E
4.64x
PEG Ratio
-3.12x
P/B
3.53x
P/S
1.71x
P/FCF
4.06x
EV/EBITDA
4.57x
Shares Out
39.7M
Financials (TTM)
Revenue
$780.6M
Net Income
$62.9M
EBITDA
$401.0M
Free Cash Flow
$327.6M
Op Cash Flow
$329.3M
EPS Basic
$1.98
EPS Diluted
$1.73
EPS Forward
$7.24
Gross Margin
59.4%
Op Margin
24.0%
Net Margin
8.1%
Balance Sheet
Total Assets
$1.66B
Total Liab.
$1.36B
Total Equity
$301.7M
Cash
$406.5M
LT Debt
$906.0M
Book Value/Sh
$9.51
Debt/Equity
3.12x
Current Ratio
1.57
Quick Ratio
1.48
Returns & Growth
ROE
5.6%
ROA
1.0%
ROIC
10.2%
Rev Growth YoY
+23.6%
EPS Growth YoY
-7.5%
Price Returns
2W
-3.5%
1M
-0.4%
3M
-19.3%
6M
-28.0%
12M
+15.3%
Technicals
52W High
$49.84
52W Low
$29.57
50d MA
$34.14
200d MA
$39.30
RSI (14)
49.70
ATR (14)
$1.32
Beta
0.77
Avg Volume
417K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$58.00
High
$60.00
Low
$56.00
Median
$58.00
Data updated apr 25, 2026 2:36am
· Source: financialmodelingprep.com